Profile data is unavailable for this security.
About the company
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
- Revenue in USD (TTM)2.24bn
- Net income in USD385.90m
- Incorporated1996
- Employees1.70k
- LocationNeurocrine Biosciences Inc6027 EDGEWOOD BEND COURTSAN DIEGO 92130United StatesUSA
- Phone+1 (858) 617-7600
- Fax+1 (858) 617-7602
- Websitehttps://www.neurocrine.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tempus AI Inc | 640.44m | -800.71m | 8.26bn | 2.30k | -- | 151.72 | -- | 12.90 | -8.29 | -8.29 | 4.44 | 0.3459 | -- | -- | -- | -- | -- | -- | -- | -- | 53.18 | -- | -116.06 | -- | 2.55 | -14.95 | 0.891 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
| Revolution Medicines Inc | 742.00k | -567.06m | 9.55bn | 490.00 | -- | 6.08 | -- | 12,872.64 | -3.59 | -3.59 | 0.0047 | 9.34 | 0.0005 | -- | 4.80 | 1,962.96 | -41.28 | -29.76 | -44.46 | -32.59 | -- | -- | -76,423.31 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Exact Sciences Corp | 2.69bn | -214.04m | 9.82bn | 6.50k | -- | 3.06 | 5,387.82 | 3.65 | -1.17 | -1.17 | 14.70 | 17.35 | 0.4089 | 5.40 | 11.60 | 414,204.30 | -3.25 | -9.71 | -3.58 | -10.60 | 72.96 | 74.10 | -7.95 | -28.21 | 1.93 | -- | 0.4459 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.06bn | 413.08m | 9.93bn | 20.00k | 24.24 | 2.63 | 12.93 | 2.45 | 8.01 | 8.01 | 78.63 | 73.97 | 0.5203 | 8.27 | 5.23 | 203,045.80 | 5.48 | 6.46 | 6.33 | 7.62 | 35.93 | 36.99 | 10.54 | 11.58 | 1.14 | 4.96 | 0.3784 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Exelixis Inc | 2.08bn | 466.92m | 9.95bn | 1.31k | 22.20 | 4.37 | 20.11 | 4.78 | 1.57 | 1.57 | 6.92 | 7.96 | 0.7012 | 3.39 | 8.04 | 1,589,006.00 | 15.73 | 8.86 | 18.08 | 9.91 | 96.25 | 96.30 | 22.43 | 15.43 | 3.88 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Sarepta Therapeutics Inc | 1.64bn | 121.85m | 10.55bn | 1.31k | 90.87 | 8.64 | 65.77 | 6.43 | 1.22 | 1.22 | 16.30 | 12.79 | 0.489 | 0.5703 | 4.35 | 1,248,362.00 | 3.63 | -21.63 | 4.38 | -25.75 | 85.92 | 86.65 | 7.43 | -77.05 | 3.03 | -- | 0.5013 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Medpace Holdings Inc | 2.07bn | 365.57m | 10.62bn | 5.90k | 29.93 | 12.03 | 26.94 | 5.13 | 11.42 | 11.42 | 64.70 | 28.42 | 1.16 | -- | 6.85 | 350,994.30 | 20.48 | 13.94 | 43.51 | 23.18 | 29.69 | 28.84 | 17.66 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Vaxcyte Inc | 0.00 | -507.65m | 11.02bn | 254.00 | -- | 3.22 | -- | -- | -4.55 | -4.55 | 0.00 | 27.47 | 0.00 | -- | -- | 0.00 | -20.08 | -34.22 | -20.95 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| BIO-TECHNE Corp | 1.17bn | 150.68m | 11.29bn | 3.10k | 75.57 | 5.28 | 43.09 | 9.64 | 0.9402 | 0.9402 | 7.29 | 13.46 | 0.4267 | 2.15 | 5.47 | 377,930.00 | 5.49 | 9.42 | 5.77 | 10.04 | 65.93 | 67.29 | 12.86 | 21.41 | 3.26 | 18.07 | 0.123 | 22.79 | 1.97 | 10.17 | -41.07 | 11.86 | 19.87 | 0.00 |
| Neurocrine Biosciences, Inc. | 2.24bn | 385.90m | 12.66bn | 1.70k | 33.47 | 4.65 | 30.75 | 5.64 | 3.73 | 3.73 | 21.67 | 26.87 | 0.7027 | 0.8901 | 4.99 | 1,602,000.00 | 12.09 | 9.77 | 14.67 | 12.19 | 98.52 | 98.51 | 17.21 | 14.79 | 4.26 | 10.28 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Insmed Inc | 342.96m | -864.29m | 13.20bn | 912.00 | -- | 27.31 | -- | 38.50 | -5.56 | -5.56 | 2.21 | 2.70 | 0.2031 | 0.8848 | 8.81 | 376,050.40 | -51.17 | -40.96 | -59.16 | -46.88 | 77.25 | 77.99 | -252.01 | -212.92 | 5.99 | -18.41 | 0.6702 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Summit Therapeutics Inc | 0.00 | -196.68m | 13.58bn | 105.00 | -- | 31.00 | -- | -- | -0.2768 | -0.2768 | 0.00 | 0.5941 | 0.00 | -- | -- | 0.00 | -54.53 | -77.32 | -71.71 | -86.35 | -- | -- | -- | -20,989.46 | -- | -- | 0.053 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Moderna Inc | 5.08bn | -2.22bn | 14.72bn | 5.60k | -- | 1.23 | -- | 2.90 | -5.81 | -5.81 | 13.14 | 30.98 | 0.2883 | 2.44 | 2.96 | 907,321.40 | -12.62 | 20.95 | -15.52 | 29.51 | 78.43 | -- | -43.77 | 32.10 | 4.20 | -- | 0.0521 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| United Therapeutics Corporation | 2.76bn | 1.11bn | 16.40bn | 1.17k | 16.15 | 2.69 | 13.93 | 5.95 | 22.75 | 22.75 | 56.36 | 136.74 | 0.3897 | 2.43 | 9.18 | 2,359,760.00 | 15.71 | 10.38 | 17.73 | 11.27 | 88.94 | 91.47 | 40.31 | 29.25 | 4.41 | -- | 0.0615 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
Data as of Nov 22 2024. Currency figures normalised to Neurocrine Biosciences Inc's reporting currency: US Dollar USD
38.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 10.84m | 10.74% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 9.84m | 9.75% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 5.15m | 5.10% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 2.57m | 2.55% |
| Bellevue Asset Management AGas of 30 Sep 2024 | 1.86m | 1.85% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.86m | 1.84% |
| AQR Capital Management LLCas of 30 Sep 2024 | 1.84m | 1.83% |
| Citadel Advisors LLCas of 30 Sep 2024 | 1.69m | 1.67% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 1.58m | 1.57% |
| Dodge & Coxas of 30 Sep 2024 | 1.29m | 1.28% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
